---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-23-000027"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:12:23.511872+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q3 2023: $637M Adj Cash Receipts (+7% YoY); raises FY23 guidance

## Summary
- Adjusted Cash Receipts of $637M (+7% YoY); operating cash flow $574M (+6%).
- Raised FY 2023 guidance for Adjusted Cash Receipts to $2,950M-$3,000M (prev. $2,900M-$2,975M).
- Year-to-date announced transactions of up to $3.8B, including $2.1B in upfront payments.
- CF franchise royalties $238M (+14%); Trelegy $58M (+36%); Evrysdi $16M (+64%).

## SEC filing metadata
- accession: 0001802768-23-000027
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/0001802768-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/rprx-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-23-000027
- JSON: https://secwatch.observer/filing/0001802768-23-000027.json
- Plain text: https://secwatch.observer/filing/0001802768-23-000027.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its the quarter ended September 30, 2023 guidance (raised).
  - Period: the quarter ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On November 8, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/0001802768-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.